Important announcements in Hong Kong stocks today:

1) Company News

$COUNTRY GARDEN (02007.HK)$In November, the contract sales amount attributable to the company's shareholders' equity was approximately 3.01 billion yuan.

$TRULY INT'L (00732.HK)$In the first 11 months, the cumulative comprehensive operating net amount was approximately 16.263 billion Hong Kong dollars, an increase of approximately 16.0%.

$JINGRUI HLDGS (01862.HK)$In the first 11 months, the cumulative contract sales were 1.91 billion yuan, a decrease of 46.41% year-on-year.

$YUEXIUTRANSPORT (01052.HK)$Intends to sell 60% equity of Tianjin JinFu Expressway Co., Ltd. to Tianjin Expressway Group Co., Ltd. for RMB 0.1908 billion. The target company is mainly engaged in the construction, operation, management, and maintenance of the Tianjin-Xiongxian Expressway.

$MEITU (01357.HK)$Sold all held cryptos and made a profit of approximately $79.63 million.

Meitu has been selling its purchased cryptos in the market since November 2024. As of December 4, 2024, all purchased cryptos held have been sold (about 31,000 units of Ethereum and 940 units of Bitcoin), with total cash consideration of approximately $0.1 billion and $0.08 billion respectively. The sales generated a profit of approximately $79.63 million (equivalent to about RMB 0.571 billion). The board of directors intends to use approximately 80% of the net profit from the sales for paying special dividends, while the remaining net profit will be used as general operating funds to expand the group's image and design product business primarily based on a subscription model.

$CHINARES PHARMA (03320.HK)$ ChinaRes Pharmaceutical Commerce plans to issue asset-backed notes in installments with a total principal amount of RMB 15 billion.

$WATER OASIS GP (01161.HK)$Issue a profit warning, expecting annual net income of approximately 65 million HK dollars to 69 million HK dollars.

$TSAKER NE (01986.HK)$Completed the sale of about 3.76% equity stake in Tsaker Technology, involving 39.9752 million yuan.

$GAPACK (00468.HK)$Discussions and negotiations regarding a possible management buyout are still ongoing.

$XIWANG PROPERTY (02088.HK)$Negotiations between administrators and potential third-party buyers are ongoing, actively seeking other potential buyers.

$BABYTREE GROUP (01761.HK)$The listing committee will delist the company's shares.

$SKB BIO-B (06990.HK)$On December 4th, the company received a clinical trial notification letter for the clinical trial application of the innovative drug SKB500 developed by the company, approved by the Drug Evaluation Center of the National Medical Products Administration.

The announcement states that SKB500 is a new ADC drug developed by the company using the OptiDC™ platform technology, targeting the biological characteristics of the target, with independent intellectual property rights, showing good efficacy and safety profile in preclinical studies, intended for the treatment of advanced solid tumors.

$HENLIUS (02696.HK)$The listing registration application for the biosimilar drug HLX11 of beigene has been accepted by the National Medical Products Administration.

2) Repurchase Dynamics

$NCI (01336.HK)$、 $HAITONG SEC (06837.HK)$ New China Life Insurance Asset Management Co., Ltd. increased its shareholding by buying 8 million shares on December 3, 2024, at a price of 7.0674 Hong Kong dollars per share, increasing its stake in the H-share by 5.7192%.

Data shows that this is the first time in five years that the insurance funds have taken a stake in a brokerage firm. New China Life Insurance continued to buy shares of Haitong Securities H-share after reaching the triggering threshold on November 28.

$BEIGENE (06160.HK)$Shareholder HHLR Fund, L.P. and its affiliates collectively reduced their shareholding by approximately 21.9973 million shares of the company, reducing their ownership percentage to 9.02%.

$GAC GROUP (02238.HK)$In November, the accumulated repurchase of H-share shares amounted to 25.524 million shares, with a repurchase range of 2.29 Hong Kong dollars to 3.12 Hong Kong dollars, totaling 0.454 billion Hong Kong dollars in transaction value.

$TENCENT (00700.HK)$The company spent approximately 0.7 billion Hong Kong dollars to repurchase 1.74 million shares, with a repurchase price range of 399.8 Hong Kong dollars to 405.4 Hong Kong dollars.

$AIA (01299.HK)$The company spent 62.3037 million Hong Kong dollars to repurchase 1.0816 million shares, with a repurchase price range of 57.4 to 57.95 Hong Kong dollars.

$SHANGHAI PECHEM (00338.HK)$The company spent 1.2246 million Hong Kong dollars to repurchase 1.048 million shares, with a repurchase price range of 1.16 to 1.18 Hong Kong dollars per share.

Editor/Danial